Last reviewed · How we verify
PF-06940434 (pf-06940434)
PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2
Pf-06940434, developed by Pfizer Inc., was a discontinued drug. Its mechanism of action and intended indications are not available in the provided information.
At a glance
| Generic name | pf-06940434 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2 |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
Pipeline indications
- Squamous Cell Carcinoma of the Head and Neck — discontinued
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06940434 CI brief — competitive landscape report
- PF-06940434 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI